satellite symposium

Comments

Transcription

satellite symposium
SATELLITE
SYMPOSIUM
INVITATION
The European Accreditation Committee
in CNS (EACIC) has granted 2 CME
credits to this satellite symposium.
To obtain your CME credits, fill out the
evaluation form at www.eacic.eu
Treatment paradigms and importance of
outcome dimensions in schizophrenia
– patient and physician outlooks
Date: Sunday 18th September 2016
Time: 17:15–19:00
Venue: Hall F2
Moderator and Chairman: Jim van Os (The Netherlands)
Faculty: Peter Haddad (UK), Pierre-Michel Llorca (France),
Wolfgang Fleischhacker (Austria), Ofer Agid (Canada)
Satellite symposium on the occasion of the 29th ECNP Congress,
with educational financial support provided by Otsuka
Pharmaceutical Europe Ltd. and H. Lundbeck A/S
Date of preparation: June 2016. OPEL/0716/MTN/1603
XX-ABIM-2016.06-00007710
Treatment paradigms
and importance of
outcome dimensions in
schizophrenia – patient
and physician outlooks
AGENDA
17:15–17:25
Welcome; introduction to symposium format; set scene for Debate 1
Debate 1:
Jim van Os
(The Netherlands)
Managing schizophrenia: short-term benefit vs. long-term success 17:25–17:40
Short-term treatment outcome should be Peter Haddad
prioritised in schizophrenia(UK)
17:40–17:55
Long-term treatment outcome should be Pierre-Michel Llorca
prioritised in schizophrenia(France)
17:55–18:10
Summary and consensus Debate 2:
Jim van Os
(The Netherlands)
Managing schizophrenia: symptom control vs. improved functioning
18:10–18:15
Set scene for Debate 2 Jim van Os
(The Netherlands)
18:15–18:30
Symptomatic control should be prioritised Wolfgang Fleischhacker
in the treatment of schizophrenia(Austria)
18:30–18:45
Patient functioning and health-related Ofer Agid
quality of life (HRQoL) should be prioritised(Canada)
in the treatment of schizophrenia
18:45–19:00
Summary and consensus; closure Jim van Os
(The Netherlands)

Similar documents

Schizophrenia Treatment Market to Make Great Impact In Near Future by 2026

Schizophrenia Treatment Market to Make Great Impact In Near Future by 2026 Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and restore one’s ability to function and enjoy a meaningful life. The signs of schizophrenia are different for everyone. Symptoms may develop slowly over months or years, or may appear very abruptly. The disease may come and go in relapse and remission. Hence, recovery from schizophrenia is a lifelong process. SchizophreniaTreatment Market: Drivers and Restraints

More information

Schizophrenia Market Share, Size, Growth, Analysis, Overview and Pipeline Review, H1 2016

Schizophrenia Market Share, Size, Growth, Analysis, Overview and Pipeline Review, H1 2016 Global Markets Direct's, 'Schizophrenia - Pipeline Review, H1 2016', provides an overview of the Schizophrenia pipeline landscape. Visit us @ http://www.radiantinsights.com/research/schizophrenia-pipeline-review-h1-2016

More information